Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

The protocol presents a cancer immunotherapy model using cell-based tumor vaccination with Flt3L-expressing B16-F10 melanoma. This protocol demonstrates the procedures, including preparation of cultured tumor cells, tumor implantation, cell irradiation, measurement of tumor growth, isolation of intratumoral immune cells, and flow cytometry analysis.

Abstract

Fms-like tyrosine kinase 3 ligand (Flt3L) is a hematopoietic cytokine that promotes the survival and differentiation of dendritic cells (DCs). It has been used in tumor vaccines to activate innate immunity and enhance antitumor responses. This protocol demonstrates a therapeutic model using cell-based tumor vaccine consisting of Flt3L-expressing B16-F10 melanoma cells along with phenotypic and functional analysis of immune cells in the tumor microenvironment (TME). Procedures for cultured tumor cell preparation, tumor implantation, cell irradiation, tumor size measurement, intratumoral immune cell isolation, and flow cytometry analysis are described. The overall goal of this protocol is to provide a preclinical solid tumor immunotherapy model, and a research platform to study the relationship between tumor cells and infiltrating immune cells. The immunotherapy protocol described here can be combined with other therapeutic modalities, such as immune checkpoint blockade (anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies) or chemotherapy in order to improve the cancer therapeutic effect of melanoma.

Introduction

Cancer immunotherapy has been recognized as a promising therapeutic strategy based on its less toxic side effects and more durable responses. Several types of immunotherapies have been developed, including oncolytic virus therapies, cancer vaccines, cytokine therapies, monoclonal antibodies, adoptive cell transfer (CAR-T cells or CAR-NK), and immune checkpoint blockade1.

For cancer vaccines, there are different forms of therapeutic vaccines, such as whole cell-based vaccines, protein or peptide vaccines, and RNA or DNA vaccines. Vaccination relies on the ability of antigen-presenting cells (APCs) to process tumor ant....

Protocol

All mice used in the study were maintained and housed in the vivarium of the La Jolla Institute for Immunology (LJI) under specific pathogen-free conditions with controlled temperature and humidity. Animal experiments were performed with 8-14 weeks old female C57BL/6 mice according to guidelines and protocols approved by the LJI Animal Care Committee.

1. Preparation of cultured tumor cells for implantation

  1. Culture B16-F10 melanoma cells in Iscove's Modified Dul.......

Representative Results

A visible black dot of the implanted B16-F10 cells is usually observed on the skin surface ~3 days after tumor implantation. Mice are treated with the tumor vaccine 3, 6, and 9 days after the tumor nodule has reached a size of ≥2 mm. We observed a significant reduction in tumor growth in vaccinated mice group ~2 weeks after tumor implantation (Figure 1). At the end of the experiment, we isolated the intratumoral immune cells and analyzed their number and cell surface marker expression,.......

Discussion

The protocol described here is based on the study by Allison's group. They demonstrated that combination of B16-Flt3L vaccine with CTLA-4 blockade showed a synergistic effect on survival rate and tumor growth, whereas no reduction of tumor growth was seen in mice receiving the B16-Flt3L vaccine or anti-CTLA-4 antibody treatment alone7. Recent studies have revealed a novel Treg-intrinsic CTLA4-PKCη signaling pathway that plays an important obligatory role in regulating the contact-dependen.......

Acknowledgements

We thank Dr. Stephen Schoenberger for providing B16-Flt3L cells and the staff of the LJI animal and flow cytometry facilities for excellent support.

....

Materials

NameCompanyCatalog NumberComments
0.25% trypsin-EDTA Gibco25200-056
10% heat-inactivated FBSOmega ScientificFB-02 Lot# 209018
30G needleBD Biosciences305106
96 well V-shape-bottom plateSARSTEDT83.3926.500
B16 cell line expressing Fms-like tyrosine kinase 3 ligand (B16-Flt3L)Gift of Dr. Stephen Schoenberger, LJI Flt3L cDNAs were cloned into the pMG-Lyt2 retroviral vector, as in refernce 5, Supplemental Figure 1
B16-F10 cell linesATCCCRL-6475
Centrifuge 5810REppendorf
Cytofix fixation buffer BD BiosciencesBDB554655Cell fixation buffer (4.2% PFA) 
Cytofix/Cytoperm kit BD Biosciences554714Fixation/Permeabilization Solution Kit
DNase ISigma11284932001
Dulbecco's Modified Eagle Medium  (DMEM) Corning10013CV
Electronic digital caliperFisherbrand14-648-17
FlowJo software Tree StarFlow cytometer data analysis
GolgiStop (protein transport inhibitor)BD Biosciences5547241:1500 dilution
HEPES (1M)Gibco15630-080
IonomycinSigmaI0634
Iscove’s modified Dulbecco’s medium (IMDM)Thermo Fisher12440053
LSR-II cytometers BD BiosciencesFlow cytometer
MEM nonessential amino acidsGibco11140-050
penicillin and streptomycin Gibco15140-122
Percoll GE Healthcare Life SciencesGE17-0891-02density gradient specific medium
PMASigmaP1585
Red Blood Cell Lysing Buffer Hybri-Max liquidSigmaR7757-100ML
RPMI 1640 mediumCorning10-040-CV
RS2000 X-ray IrradiatorRad Source Technologies
sodium pyruvateGibco11360-070
Sterile cell strainer 40 μmFisherbrand22-363-547
Sterile cell strainer 70 μmFisherbrand22-363-548
TL LiberaseRoche477530
Zombie Aqua fixable viability kitBioLegend423101
Antibodies
Anti-mCD45BioLegend103135Clone: 30-F11
Fluorophore: BV570
Dilution: 1:200
Anti-mCD3εBioLegend100327Clone: 145-2C11
Fluorophore: PerCP-Cy5.5
Dilution: 1:200
Anti-mCD8BioLegend100730
100724
Clone: 53-6.7
Fluorophore: Alexa Fluor 700, Alexa Fluor 647
Dilution: 1:200
Anti-mCD4BioLegend100414Clone: GK1.5
Fluorophore: APC-Cy7
Dilution: 1:200
Anti-mFoxp3Thermo Fisher Scientific11577382Clone: FJK-16s
Fluorophore: FITC
Dilution: 1:100
Anti-m/hGzmBBioLegend372208Clone: QA16A02
Fluorophore: PE
Dilution: 1:100
Anti-mIFNgBioLegend505826Clone: XMG1.2
Fluorophore: PE-Cy7
Dilution: 1:100
Anti-mCD19BioLegend115543Clone: 6D5
Fluorophore: BV785
Dilution: 1:100
Anti-mGr1BioLegend108423Clone: RB6-8C5
Fluorophore: APC/Cy7
Dilution: 1:200
Anti-mCD11bBioLegend101223Clone: M1/70
Fluorophore: Pacific blue
Dilution: 1:100
Anti-mF4/80BioLegend123114Clone: BM8
Fluorophore: PECy7
Dilution: 1:100
Anti-mCD11cBioLegend117328Clone: N418
Fluorophore: PerCP Cy5.5
Dilution: 1:100
Anti-mMHCIIBioLegend107622Clone: M5/114.15.2
Fluorophore: AF700
Dilution: 1:400
Anti-mCD103BioLegend121410Clone: 2E7
Fluorophore: Alexa Fluor 647
Dilution: 1:200
Anti-mCD86BioLegend105007Clone: GL-1
Fluorophore: PE
Dilution: 1:200
FC-blocker (Rat anti-mouse CD16/CD32)BD Biosciences553141Clone: 2.4G2
Dilution: 1:200

References

  1. Zhang, Y., Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell & Molecular Immunology. 17 (8), 807-821 (2020).
  2. Banchereau, J., Steinman, R. M.

Explore More Articles

MelanomaImmunotherapyTumor VaccinationHematopoietic CytokineB16 F10 CellsTumor ImplantationTumor MeasurementGamma IrradiationCell Viability

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved